Lisata Therapeutics Inc. (LSTA)
NASDAQ: LSTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LSTA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $647.45K
- EPS (TTM)
- -$28.20
- Dividend yield
- None
- 52-week range
- 0.85 – 76.05
- Day range
- 0.85 – 0.90
- Volume / Avg
- 139.26K / 13.46K
- Beta
- —
- Shares outstanding
- 720.27K
52-week range
LSTA stock today
Shares of Lisata Therapeutics (LSTA) finished lower on Nov 20 at $0.8989, a drop of 1.22% or $0.0111 per share, versus the S&P 500's 3.70% decline. Volume was 10.3x the average at 139.26K shares, a sign of unusually heavy trading. At this level, LSTA sits near the bottom of its 52-week range of $0.85 to $76.05: 98.8% below the high and 5.8% above the low.
LSTA is down 51.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.1%. Lisata Therapeutics has posted a net loss over the last twelve months (EPS of -$28.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lisata Therapeutics
Company profileLisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
- Headquarters
- Basking Ridge, NJ
- Employees
- 21
- Website
- lisata.com
Financial highlights
Full financialsIn fiscal 2024, Lisata Therapeutics generated $170,000 in revenue, down 83.0% from fiscal 2024, its first annual decline since 2011. Lisata Therapeutics reported a net loss of $16.6 million, compared with a loss of $20.0 million a year earlier. Operating margin was -10711.2%.
| Fiscal year | FY 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $170.00K | $1.00M | $0 | $0 | — |
| Growth | -83.00% | — | — | — | — |
| Net income | $-16.59M | $-19.98M | $-20.84M | $-54.23M | $-27.47M |
| EPS (diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
Analyst forecast
ForecastConsensus (2 analysts)
none
- Strong buy 0
- Buy 0
- Hold 2
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.73 vs —
LSTA news
All LSTA news- Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026GlobeNewswire
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicineGlobeNewswire
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor ConferencesGlobeNewswire
- Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsGlobeNewswire
Lisata Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OGENOragenics Inc. | 0.157 | -8.72% | $708.38K | vs LSTA |
| SPRCSciSparc Ltd. | 0.1955 | -34.83% | $481.60K | vs LSTA |
| CDTCDT Equity Inc. | 0.23 | -13.89% | $437.03K | vs LSTA |
| MTNBMatinas Biopharma Holdings Inc. | 0.7999 | -1.26% | $890.71K | vs LSTA |
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 1.88 | -3.85% | $982.95K | vs LSTA |
| GOVXGeoVax Labs Inc. | 1.81 | -5.24% | $985.46K | vs LSTA |
| SXTCChina SXT Pharmaceuticals Inc. | 2.65 | +2.12% | $273.95K | vs LSTA |
| ARTLArtelo Biosciences Inc. | 1.39 | -4.14% | $1.30M | vs LSTA |
Indexes, lists and sector
Lisata Therapeutics stock FAQ
What is Lisata Therapeutics's stock price today?
LSTA last traded at $0.8989 as of Nov 20, 4:00 PM EST, down 1.22% on the day. Prices are delayed at least 15 minutes.
Does Lisata Therapeutics pay a dividend?
No. Lisata Therapeutics does not currently pay a regular cash dividend.
Who is Lisata Therapeutics's CEO?
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. is the chief executive officer of Lisata Therapeutics Inc., which has about 21 employees.
Has LSTA ever split its stock?
Yes. The most recent LSTA stock split was a 1-for-15 split on Nov 23, 2026, one of 6 splits on record.
What is the LSTA 52-week high?
The 52-week high for LSTA is $76.05 and the 52-week low is $0.85. The stock is currently 98.8% below its high.